UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

UBS expects investors to wage small attraction to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with absorption shifting alternatively to a strategy update from caller main enforcement Luke Miels.

The slope reiterated its 'neutra'l standing connected GSK up of results and a superior markets time owed connected 28 July.

UBS acceptable a 12-month terms people of 1,940 pence, adjacent to the 1,957 pence astatine which the shares closed connected 10 July.

Its forecasts beryllium astir 1% beneath statement connected second-quarter sales, operating nett and earnings.

The slope said the cardinal statement was whether Miels could acceptable retired a credible way to GSK's people of much than £40 cardinal successful risk-adjusted income by 2031.

UBS does not expect that people to change, but flagged a shortfall of much than £4 cardinal betwixt the company's ambition and its ain and statement forecasts.

The slope expects an update connected however GSK is reprioritising its pipeline aft its caller acquisition of Nuvalent.

UBS besides pointed to weakness successful the specialty and respiratory businesses seen successful the archetypal quarter.

It flagged a slowdown successful United States prescriptions for the respiratory treatments Trelegy, Breo and Anoro truthful acold successful 2026.

The slope named late-stage information connected the chronic cough attraction camlipixant arsenic an important focus, noting GSK's highest income ambition of much than £2.5 cardinal against its ain forecast of £1.1 billion.

UBS besides highlighted a Delaware tribunal proceedings moving from 14 to 17 July implicit AnaptysBio's declaration claims relating to the crab cause Jemperli.

The slope said outcomes could scope from nary alteration to existing presumption to, successful an utmost scenario, GSK losing rights to the drug.

UBS forecasts full-year gross of £33.4 billion, up from £32.7 cardinal successful 2025, and halfway net of 175.5 pence a share.

That maturation of astir 4% sits good beneath the company's guidance for a 7% to 9% summation astatine changeless currency.

UBS makes a marketplace successful GSK securities and holds a agelong presumption of 0.5% oregon much successful its shares.